Astatine 211
Astatine 211
Astatine 211
No carrier added
IONETIX produces Astatine-211 in the Lansing, Michigan facility. Astatine-211 is currently considered as one of the most promising alpha particle emitters for application in targeted alpha therapy (TAT) of cancers (Eychenne et al. 2021), a modality that is experiencing an increasing interest and is expected to have a strong impact on cancer treatment in the coming years (Jang et al. 2023; Miederer et al. 2024).1
1 Vanermen, M., Ligeour, M., Oliveira, MC. et al. Astatine-211 radiolabelling chemistry: from basics to advanced biological applications. EJNMMI radiopharm. chem. 9, 69 (2024). https://doi.org/10.1186/s41181-024-00298-4
A centrally located isotope manufacturing facility located in Lansing, Michigan
This first-of-kind facility is dedicated exclusively to producing alpha-emitting isotopes, including Ac-225, At-211 and Pb-212, using IONETIX’s proprietary cyclotron accelerator technology. The company completed the installation and commissioning of the first cyclotron at the facility in 2023. A second cyclotron will be installed and commissioned in early 2025, adding both scalable supply capacity and onsite production redundancy. A second site at another US location is planned for 2026.
